WallStreetZenWallStreetZen

NASDAQ: TRIB
Trinity Biotech PLC Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their TRIB stock forecasts and price targets.

Forecast return on equity

Is TRIB forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is TRIB forecast to generate an efficient return on assets?
Company
-167.36%
Industry
10.13%
TRIB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TRIB earnings per share forecast

What is TRIB's earnings per share in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$1.91
Avg 2 year Forecast
-$1.03

TRIB revenue forecast

What is TRIB's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$65.6M+11.76%
Avg 2 year Forecast
$72.0M+22.76%
TRIB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TRIB revenue growth forecast

How is TRIB forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
11.76%
Industry
4.72%
Market
9.98%
TRIB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TRIB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TRIB vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
TRIB$1.20N/AN/A
XWEL$1.73N/AN/A
CHEK$1.43N/AN/A
PRPO$6.80N/AN/A
MDXH$2.00N/AN/A

Trinity Biotech Stock Forecast FAQ

What is TRIB's earnings growth forecast for 2024-2025?

(NASDAQ: TRIB) Trinity Biotech's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 45.01%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.18%.

Trinity Biotech's earnings in 2024 is -$22,296,000.On average, 1 Wall Street analyst forecast TRIB's earnings for 2024 to be -$292,822,642, with the lowest TRIB earnings forecast at -$292,822,642, and the highest TRIB earnings forecast at -$292,822,642.

In 2025, TRIB is forecast to generate -$157,909,593 in earnings, with the lowest earnings forecast at -$157,909,593 and the highest earnings forecast at -$157,909,593.

If you're new to stock investing, here's how to buy Trinity Biotech stock.

What is TRIB's revenue growth forecast for 2024-2025?

(NASDAQ: TRIB) Trinity Biotech's forecast annual revenue growth rate of 11.76% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.72%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.98%.

Trinity Biotech's revenue in 2024 is $58,652,000.On average, 1 Wall Street analysts forecast TRIB's revenue for 2024 to be $10,049,489,116, with the lowest TRIB revenue forecast at $10,049,489,116, and the highest TRIB revenue forecast at $10,049,489,116.

In 2025, TRIB is forecast to generate $11,038,340,448 in revenue, with the lowest revenue forecast at $11,038,340,448 and the highest revenue forecast at $11,038,340,448.

What is TRIB's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: TRIB) forecast ROA is -167.36%, which is lower than the forecast US Diagnostics & Research industry average of 10.13%.

What is TRIB's Earnings Per Share (EPS) forecast for 2024-2025?

(NASDAQ: TRIB) Trinity Biotech's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that TRIB's EPS will be -$1.91 for 2024, with the lowest EPS forecast at -$1.91, and the highest EPS forecast at -$1.91. In 2025, TRIB's EPS is forecast to hit -$1.03 (min: -$1.03, max: -$1.03).

What is TRIB's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: TRIB) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.